PAKT

NCT02423603 📎

Regimen

Experimental
Capivasertib 400 mg BID D2-5 weekly + paclitaxel 90 mg/m2 D1,8,15 Q4W.
Control
Placebo + paclitaxel on same schedule.

Population

Metastatic or locally advanced triple-negative breast cancer, no prior chemotherapy for advanced disease; biomarker subgroup defined by PIK3CA/AKT1/PTEN alterations.

Key finding

PAKT demonstrated capivasertib + paclitaxel extended PFS and suggested OS benefit in 1L metastatic TNBC, particularly in PIK3CA/AKT1/PTEN-altered tumors. Supported pivot of capivasertib development toward HR+ (CAPItello-291).

Source: PMID 31841354

Timeline

  • Publication: 2020 Feb 10

Guideline citations

  • NCCN BREAST